bioRxiv · 10.64898/2026.06.15.732285
Autoimmune diabetes-dependent c-Maf SUMOylation licenses inflammatory bowel disease by reshaping the gut microbiota
Abstract
We have previously demonstrated a critical role of c-Maf SUMOylation in the regulation of autoimmune diabetogenesis, but its physiological relevance to and potential clinical impact on gut inflammation need further elucidation. Here, integrating a 14-year population-based time-trend cohort study of 139,204 type 1 diabetes patients with experiments in non-obese diabetic mice, we illustrated that autoimmune diabetes confers resistance to colitis mediated by an impaired c-Maf SUMOylation-driven IL-21-IgA axis. Utilizing T cell-specific c-Maf SUMOylation site-mutated mice, we further demonstrated that SUMOylation-defective c-Maf enhances IL-21 expression in CD4+ T cells to promote fecal IgA production and colitis resistance via microbiota remodeling, specifically through Lactobacillus johnsonii enrichment and activating lithocholic acid (LCA)-mediated AMPK anti-inflammatory pathway. Pharmacological HDAC2 inhibition by BRD6688 promotes c-Maf-mediated IL-21 and suppresses colitis in PBMC-humanized mice. Altogether, we revealed how SUMOylation reciprocally modulates the inflammatory process between autoimmune diabetes and colitis in a T cell-restricted and single transcription factor-based manner.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Hsu, C.-Y., Tsai, Y.-W., Fu, S.-H., Liu, Y.-W., Dong, J.-L., Yang, Y.-J., Mai, Y.-W., Tsai, L.-C., Wu, C.-E., Liang, H.-I., Sun, C.-C., Chen, C.-T., Wang, S.-P., Miaw, S.-C., Sytwu, H.-K.. 2026-06-19. Autoimmune diabetes-dependent c-Maf SUMOylation licenses inflammatory bowel disease by reshaping the gut microbiota. https://doi.org/10.64898/2026.06.15.732285
Cite the original work for its findings. Save a collection to share your selection of sources.